AU Patent

AU2017274293A1 — Treatment of intrahepatic cholestatic diseases

Assigned to CymaBay Therapeutics Inc · Expires 2018-12-13 · 7y expired

What this patent protects

Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.

USPTO Abstract

Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.

Drugs covered by this patent

seladelpar-lysine (SELADELPAR LYSINE)

Patent Metadata

Patent number: AU2017274293A1
Jurisdiction: AU
Classification: —
Expires: 2018-12-13
Drug substance claim: No
Drug product claim: No
Assignee: CymaBay Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.